FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2589138774> ?p ?o ?g. }

• W2589138774 endingPage "e0005389" @default.
• W2589138774 startingPage "e0005389" @default.
• W2589138774 abstract "Background In 2014–2015, we assessed favipiravir tolerance and efficacy in patients with Ebola virus (EBOV) disease (EVD) in Guinea (JIKI trial). Because the drug had never been used before for this indication and that high concentrations of the drugs were needed to achieve antiviral efficacy against EBOV, a pharmacokinetic model had been used to propose relevant dosing regimen. Here we report the favipiravir plasma concentrations that were achieved in participants in the JIKI trial and put them in perspective with the model-based targeted concentrations. Methods and findings Pre-dose drug concentrations were collected at Day-2 and Day-4 of treatment in 66 patients of the JIKI trial and compared to those predicted by the model taking into account patient’s individual characteristics. At Day-2, the observed concentrations were slightly lower than the model predictions adjusted for patient’s characteristics (median value of 46.1 versus 54.3 μg/mL for observed and predicted concentrations, respectively, p = 0.012). However, the concentrations dropped at Day-4, which was not anticipated by the model (median values of 25.9 and 64.4 μg/mL for observed and predicted concentrations, respectively, p<10−6). There was no significant relationship between favipiravir concentrations and EBOV viral kinetics or mortality. Conclusions Favipiravir plasma concentrations in the JIKI trial failed to achieve the target exposure defined before the trial. Furthermore, the drug concentration experienced an unanticipated drop between Day-2 and Day-4. The origin of this drop could be due to severe sepsis conditions and/or to intrinsic properties of favipiravir metabolism. Dose-ranging studies should be performed in healthy volunteers to assess the concentrations and the tolerance that could be achieved with high doses. Trial registration ClinicalTrials.gov NCT02329054" @default.
• W2589138774 created "2017-03-03" @default.
• W2589138774 creator A5005382719 @default.
• W2589138774 creator A5013536211 @default.
• W2589138774 creator A5015556391 @default.
• W2589138774 creator A5024120430 @default.
• W2589138774 creator A5031224690 @default.
• W2589138774 creator A5033156784 @default.
• W2589138774 creator A5033366789 @default.
• W2589138774 creator A5047288191 @default.
• W2589138774 creator A5048145311 @default.
• W2589138774 creator A5051182495 @default.
• W2589138774 creator A5053644134 @default.
• W2589138774 creator A5063547176 @default.
• W2589138774 creator A5067395185 @default.
• W2589138774 creator A5069347591 @default.
• W2589138774 creator A5074815319 @default.
• W2589138774 creator A5075119467 @default.
• W2589138774 creator A5077430855 @default.
• W2589138774 creator A5080451499 @default.
• W2589138774 creator A5085917697 @default.
• W2589138774 creator A5087484544 @default.
• W2589138774 creator A5087626284 @default.
• W2589138774 date "2017-02-23" @default.
• W2589138774 modified "2023-10-17" @default.
• W2589138774 title "Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted" @default.
• W2589138774 cites W1812532407 @default.
• W2589138774 cites W1971292277 @default.
• W2589138774 cites W2009424749 @default.
• W2589138774 cites W2028934479 @default.
• W2589138774 cites W2030160453 @default.
• W2589138774 cites W2031438581 @default.
• W2589138774 cites W2077173768 @default.
• W2589138774 cites W2082951773 @default.
• W2589138774 cites W2090642347 @default.
• W2589138774 cites W2124676097 @default.
• W2589138774 cites W2163848439 @default.
• W2589138774 cites W2167719907 @default.
• W2589138774 cites W2268078935 @default.
• W2589138774 cites W2296414617 @default.
• W2589138774 cites W2531673672 @default.
• W2589138774 cites W2581605534 @default.
• W2589138774 cites W898301972 @default.
• W2589138774 doi "https://doi.org/10.1371/journal.pntd.0005389" @default.
• W2589138774 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5340401" @default.
• W2589138774 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28231247" @default.
• W2589138774 hasPublicationYear "2017" @default.
• W2589138774 type Work @default.
• W2589138774 sameAs 2589138774 @default.
• W2589138774 citedByCount "136" @default.
• W2589138774 countsByYear W25891387742017 @default.
• W2589138774 countsByYear W25891387742018 @default.
• W2589138774 countsByYear W25891387742019 @default.
• W2589138774 countsByYear W25891387742020 @default.
• W2589138774 countsByYear W25891387742021 @default.
• W2589138774 countsByYear W25891387742022 @default.
• W2589138774 countsByYear W25891387742023 @default.
• W2589138774 crossrefType "journal-article" @default.
• W2589138774 hasAuthorship W2589138774A5005382719 @default.
• W2589138774 hasAuthorship W2589138774A5013536211 @default.
• W2589138774 hasAuthorship W2589138774A5015556391 @default.
• W2589138774 hasAuthorship W2589138774A5024120430 @default.
• W2589138774 hasAuthorship W2589138774A5031224690 @default.
• W2589138774 hasAuthorship W2589138774A5033156784 @default.
• W2589138774 hasAuthorship W2589138774A5033366789 @default.
• W2589138774 hasAuthorship W2589138774A5047288191 @default.
• W2589138774 hasAuthorship W2589138774A5048145311 @default.
• W2589138774 hasAuthorship W2589138774A5051182495 @default.
• W2589138774 hasAuthorship W2589138774A5053644134 @default.
• W2589138774 hasAuthorship W2589138774A5063547176 @default.
• W2589138774 hasAuthorship W2589138774A5067395185 @default.
• W2589138774 hasAuthorship W2589138774A5069347591 @default.
• W2589138774 hasAuthorship W2589138774A5074815319 @default.
• W2589138774 hasAuthorship W2589138774A5075119467 @default.
• W2589138774 hasAuthorship W2589138774A5077430855 @default.
• W2589138774 hasAuthorship W2589138774A5080451499 @default.
• W2589138774 hasAuthorship W2589138774A5085917697 @default.
• W2589138774 hasAuthorship W2589138774A5087484544 @default.
• W2589138774 hasAuthorship W2589138774A5087626284 @default.
• W2589138774 hasBestOaLocation W25891387741 @default.
• W2589138774 hasConcept C112705442 @default.
• W2589138774 hasConcept C126322002 @default.
• W2589138774 hasConcept C162324750 @default.
• W2589138774 hasConcept C2777288759 @default.
• W2589138774 hasConcept C2777469322 @default.
• W2589138774 hasConcept C2779134260 @default.
• W2589138774 hasConcept C2779772310 @default.
• W2589138774 hasConcept C2781413609 @default.
• W2589138774 hasConcept C3008058167 @default.
• W2589138774 hasConcept C3018567284 @default.
• W2589138774 hasConcept C47768531 @default.
• W2589138774 hasConcept C524204448 @default.
• W2589138774 hasConcept C535046627 @default.
• W2589138774 hasConcept C71924100 @default.
• W2589138774 hasConcept C98274493 @default.
• W2589138774 hasConceptScore W2589138774C112705442 @default.
• W2589138774 hasConceptScore W2589138774C126322002 @default.
• W2589138774 hasConceptScore W2589138774C162324750 @default.

• next